Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year . TGT $10+ Cipher Pharmaceuticals (CPH.T) Market Cap: $39.7 Million CAD Cash $10.4 Million CAD Price: $1.46 Shares Out: 26.8 Million Slide Presentation https://filecache.investorroom.com/mr5ircnw_cipher/204/Cipher Presentation Novembe 19 Final.pdf Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including: Xydalba launch in first half of 2019 DTR-001 pre-clinical results in Q2 2019 Regulatory approval for plecanatide from Health Canada in Q4 2019 Regulatory approval for A-101 from Health Canada in Q4 2019 Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019 Largest Shareholder : John Douglas Mull, MD 9,911,265 Grandeur Peak Global Advisors LLC 1,522,200 Taylor Asset Management, Inc. (Canada) 243,100 Harold Morton Wolkin, CFA 184,134 Arthur M. Deboeck 104,300 Mark A. Beaudet 87,790 Christian Godin 39,009 Robert D. Tessarolo 37,013 Stephen L. Lemieux, CPA 25,008 Acadian Asset Management LLC 9,093
Loe gives a 12-month return of 257 per cent for the stock, saying the specialty pharma company’s pipeline prospects are encouraging. https://www.cantechletter.com/2019/03/cipher-pharma-has-a-huge-upside-says-echelon-wealth/
Strong insider buying in last days and many big milestones coming before year end ..Great buying opportunity here https://www.canadianinsider.com/node/7?menu_tickersearch=CPH+|+Cipher+Pharmaceuticals Cipher anticipates several key milestones in 2019 that will continue the growth of its Canadian commercial platform, including: *Regulatory approval for plecanatide from Health Canada in Q4 2019 *Regulatory approval for A-101 from Health Canada in Q4 2019 *Commercial launch of XYDALBA (dalbavancin) *North American top line results for MOB-015 in Q4 2019
Both attractive drugs below could be approved by health canada within next month which could push this low float stock significantly higher ... Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada....Dec. 18, 2018 https://cipher.investorroom.com/201...Solution-Accepted-for-Review-by-Health-Canada Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada....Dec. 17, 2018 https://cipher.investorroom.com/201...CANATIDE-Accepted-for-Review-by-Health-Canada
APPROVEEEEED Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)..Oct. 18, 2019 https://finance.yahoo.com/news/cipher-pharmaceuticals-receives-health-canada-110000703.html It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months.According to IQVIA the total Canadian laxative and antispasmodic market (prescription and OTC) was valued at over CDN $200 million for the 12 months ending December 2018. Cipher acquired the Canadian rights to develop, market, distribute and sell TRULANCE® from Bausch Health Companies Inc.